Kane W H, Majerus P W
J Biol Chem. 1981 Jan 25;256(2):1002-7.
We have purified human coagulation Factor V 6,000-fold to homogeneity from citrated plasma using polyethylene glycol 6000 precipitation, adsorption of Factor V to barium citrate, DEAE-Sepharose chromatography, and gel filtration on Ultrogel AcA 34 (yield 21%). Human Factor V is a single polypeptide chain before and after disulfide bond reduction with an apparent Mr = 335,000 as determined by electrophoresis on 5% acrylamide sodium dodecyl sulfate gels. Human Factor V is a glycoprotein containing 13% of weight carbohydrate and there is a high content of sialic acid (86 residues/mol) compared to the other sugars. When human Factor V is treated with thrombin, coagulation activity increases 25- to 30-fold to a specific activity of 1.7 to 2.0 units/microgram. Thrombin activation is accompanied by the cleavage of three bonds in the Factor V molecule. We have detected activation intermediates with apparent Mr = 295,000 and 248,000 and final products with apparent Mr = 150,000, 121,000, and a doublet at 95,000-91,000 as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The final products of thrombin activation of human Factor V and bovine Factor V are similar, yet the intermediates observed are different. This suggests that cleavages are made at similar locations in bovine and human Factor V, but that they occur in a different sequence. When human Factor V is treated with the Factor V activator from Russell's viper venom, it is split into two components with apparent Mr = 303,000 and 95,000-91,000 and is fully activated. The increase in coagulation activity observed upon treatment of human Factor V with thrombin or the Factor V activator from Russell's viper venom seems to correlate with the generation of the doublet Mr = 95,0090-91,000 component.
我们使用聚乙二醇6000沉淀、因子V吸附到柠檬酸钡、DEAE-琼脂糖层析以及在Ultrogel AcA 34上进行凝胶过滤(产率21%),从枸橼酸盐血浆中纯化人凝血因子V达6000倍至同质。人因子V在二硫键还原前后均为单条多肽链,通过在5%丙烯酰胺十二烷基硫酸钠凝胶上电泳测定,其表观Mr = 335,000。人因子V是一种糖蛋白,含13%(重量)的碳水化合物,与其他糖类相比,唾液酸含量很高(86个残基/摩尔)。用人凝血酶处理人因子V时,凝血活性增加25至30倍,比活性达到1.7至2.0单位/微克。凝血酶激活伴随着因子V分子中三个键的裂解。通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳判断,我们检测到表观Mr = 295,000和248,000的激活中间体以及表观Mr = 150,000、121,000和95,000 - 91,000处的双峰终产物。人凝血因子V和牛凝血因子V经凝血酶激活的终产物相似,但观察到的中间体不同。这表明在牛和人因子V中,裂解发生在相似位置,但顺序不同。当用人凝血因子V处理来自罗素蝰蛇毒的因子V激活剂时,它被裂解为两个组分,表观Mr分别为303,000和95,000 - 91,000,且被完全激活。用人凝血酶或来自罗素蝰蛇毒的因子V激活剂处理人因子V时观察到的凝血活性增加似乎与Mr = 95,000 - 91,000双峰组分的产生相关。